Immuno-Histochemistry
Immunohistochemistry (IHC) is a specialized laboratory technique that uses antibodies to detect specific proteins within tissue samples. It plays a crucial role in cancer diagnosis by revealing biological characteristics that cannot be seen with routine microscopy alone. By identifying these protein markers, IHC helps determine the exact type of cancer, how aggressive it is, and how it is likely to behave.
At Apollo Athenaa, immunohistochemistry is deeply integrated into our pathology workflow. It allows our specialists to go beyond confirming malignancy and precisely classify tumors, assess prognosis, and guide personalized treatment planning. This is especially important in women’s cancers, where treatment decisions often depend on the tumor’s molecular profile.
Key markers commonly evaluated include hormone receptors such as ER (estrogen receptor) and PR (progesterone receptor), which indicate hormone sensitivity and response to endocrine therapy; HER2, which identifies aggressive tumors that may benefit from targeted treatment; Ki-67, a marker of tumor growth rate; p53, associated with tumor aggressiveness and resistance patterns; and WT1, which aids in diagnosing specific gynecological cancers like high-grade serous ovarian carcinoma. Together, these markers enable accurate diagnosis and tailored, evidence-based cancer care.
